CTOs on the Move

Organovo

www.organovo.com

 
Organovo (NYSE MKT: ONVO) designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications. The Company is collaborating with pharmaceutical and academic partners to develop human biological disease models in three dimensions. These 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. In addition to numerous scientific publications, their technology has been featured in The Wall Street Journal, Time Magazine, The Economist, and other outlets. Organovo is changing the shape of medical research and practice.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.organovo.com
  • 6275 Nancy Ridge Drive Suite 110
    San Diego, CA USA 92121
  • Phone: 858.550.9994

Executives

Name Title Contact Details

Funding

Organovo raised $40M on 06/19/2015

Similar Companies

Ossium Health

Ossium is building the world`s first bone marrow bank to treat blood cancers, improve organ transplantation, and repair damage from radiation.

Code Biotherapeutics

Code Bio was founded on the belief that more can be done for people living with debilitating genetic diseases. We are driven by the potential of our transformative technology to treat the untreatable and cure the incurable. Code Bio is developing highly targeted genetic medicines with its proprietary, novel, multivalent, synthetic DNA delivery platform, 3DNA®, which has been engineered to overcome many of the challenges inherent with the delivery of genetic medicines. 3DNA offers unparalleled tissue and cell targeting specificity, improved bioavailability, capability to deliver large genetic payloads, potential ability to re-dose, and a scalable, modular, reproducible manufacturing process. Our 3DNA delivery platform is poised to transform the field of genetic medicines, enabling targeted delivery of gene therapy, RNAi and other genetic modalities. Currently we are advancing an internal pipeline of genetic medicines focused on select diseases without a cure (Duchenne`s Muscular Dystrophy and Type 1 Diabetes), as well as establishing partnerships to take forward programs in both rare and prevalent diseases.

CE and IC Inc

CE and IC Inc is a Burlington, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Woodcock Washburn

Woodcock Washburn is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AmpliMed Corporation

AmpliMed Corporation is a Tucson, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.